1. Brazil Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Blau Farmaceutica SA

Blau Farmaceutica SA

12.00
BRL
-0.60
(-4.76%)
0.94EPS
10.66P/E
2.32BMarket Cap
Nov 10Next Earn
Blau Farmaceutica SA
B3:BLAU3F
(B3)

Recent

price

12.00

P/E

ratio

10.66

div

yld

2.68%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
BRL
1.89
2.71
3.43
4.29
5.19
5.86
6.03
5.89
7.58
7.3
7.18
Revenue per Share
0.14
0.45
0.54
0.88
1.12
1.39
1.56
1.07
0.94
1.26
0.94
Basic EPS, GAAP
0.14
0.4
0.36
0.91
0.23
-0.1
-0.04
0.45
1.58
0.58
1.38
Free Cash Flow per Basic Share
0.06
0.19
0.15
0.52
1.44
0.45
0.58
0.28
0.24
0.35
0.32
Dividend per Share
0.43
0.61
0.98
1.17
0.97
7.02
7.88
8.66
9.37
7.57
10.1
Book Value per Share
0.38
0.57
0.94
1.07
0.23
6.16
6.87
7.13
7.26
5.51
7.04
Tangible Book Value per Share
228
228
228
228
228
233
233
233
231
233
249
Basic Weighted Avg Shares
431
618
782
978
1,182
1,366
1,407
1,373
1,754
1,702
1,786
Sales/Revenue/Turnover
15.35
26.4
26.17
30.81
32.9
33.44
31.98
24.41
18.65
20.77
17.27
Operating Margin (%)
9
9
10
10
17
21
22
39
52
69
75
Depreciation Expense
32
103
123
200
254
325
363
250
217
295
234
Net Income, GAAP
29.63
30.55
30.91
30.08
28.08
32.87
23.06
25.95
26.85
23.61
21.8
Effective Tax Rate (%)
7.5
16.7
15.76
20.48
21.52
23.8
25.83
18.2
12.38
17.33
13.09
Profit Margin (%)
41
24
256
239
437
1,353
1,307
1,218
1,138
1,129
1,486
Working Capital
34
1
193
204
627
281
228
534
486
314
609
LT Debt
97
138
223
266
221
1,635
1,818
1,995
2,151
2,256
2,316
Total Equity
- -
46.87
40.06
41.79
37.31
20.52
16.53
10.15
8.63
9.75
8.14
Return on Invested Capital (%)
- -
46.22
38.56
42.45
36.42
23.59
18.9
11.66
9.92
12.51
11.57
Return on Capital (%)
- -
87.46
68.16
81.88
104.43
35.01
21.01
13.07
10.43
13.3
10.17
Return on Common Equity (%)

Capital Structure

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
286
250
244
LT Borrowings
283
283
583
LT Finance Leases
30
27
25
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
300
231
231
Market Capitalization
3,245
2,379
2,317

Working Capital

BRL

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,897
1,828
2,153
Cash, Cash Equivalents & STI
615
542
885
Accounts Receivable, Net
458
473
515
Inventories
694
676
649
Total Current Liabilities
768
688
667
Payables & Accruals
- -
- -
- -
ST Debt
286
250
244
Deferred Revenue
- -
- -
- -

Growth Rates

BRL

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
134.45%
4.89%
Free Cash Flow
- -
-281.88%
-63.36%
Net Income, GAAP
- -
6.22%
35.8%
Sales/Revenue/Turnover
- -
8.2%
-2.96%
Total Cash Common Dividend
- -
-11.69%
46.15%

Quarterly Revenue

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
360
465
474
456
1,754
2025
373
465
475
389
1,702
2026
435
487
- -
- -
- -

Quarterly Earnings Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.17
0.22
0.31
0.25
0.94
2025
0.51
0.27
0.45
0.12
1.26
2026
0.17
0.23
- -
- -
- -

Quarterly Dividends Per Share

BRL

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.09
0.07
0.24
2025
0.13
- -
0.11
0.12
0.35
2026
0.01
0.07
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Blau Farmacêutica S.A. stands as a prominent pharmaceutical entity, delivering specialized medications across Latin America, specifically in Brazil, Argentina, Chile, Colombia, Ecuador, Peru, and Uruguay, with additional plasma collection operations in the United States. The company’s extensive portfolio encompasses a variety of critical therapeutic fields, including immunology, hematology, oncology, nephrology, infectology, and anesthesiology. Its offerings include a broad spectrum of pharmaceutical products such as biological and biotechnological drugs, oral and injectable treatments for cancer, specialized solutions for infectious diseases, and high-complexity hospital products. The firm also provides blood-derived products, antivirals, antiretrovirals, and a developing aesthetics line, which recently saw the introduction of its Fillage® Hyaluronic Acid products. Serving a diverse clientele, Blau caters to hospitals, private clinics, chemotherapy and hemodialysis centers, and public health institutions, while actively expanding its presence in the retail market. The company operates a sophisticated industrial complex featuring five manufacturing plants and an Active Pharmaceutical Ingredient (API) facility in Brazil, leveraging advanced technology to support its robust production capabilities. Established in 1987, Blau Farmacêutica S.A. maintains its headquarters in Cotia, Brazil. Recent strategic developments include the divestment of Prothya in late 2025 and ongoing investments in research, development, and innovation to drive future product launches and market expansion.